1. Evolocumab treatment is associated with early and sustained reductions in low-density cholesterol (LDL-C) over 30 months: final results from the pan-European observational HEYMANS registry. (3rd October 2022) Authors: Ray, K K; Perrone-Filardi, P; Ebenbichler, C; Vogt, A; Bridges, I; Sibartie, M; Dhalwani, N N Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Evolocumab use in Europe: clinical guidelines vs. reimbursement thresholds – results from the HEYMANS study. (14th October 2021) Authors: Ray, K K; Bruckert, E; Filardi, P; Ebenbichler, C; Vogt, A; Bridges, I; Sibartie, M; Dhalwani, N N Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. High long-term persistence to evolocumab treatment regimens in European clinical practice: analysis of the HEYMANS registry. (3rd October 2022) Authors: Ray, K K; Perrone-Filardi, P; Ebenbichler, C; Vogt, A; Bridges, I; Sibartie, M; Dhalwani, N N Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗